haloperidol has been researched along with Dyskinesia Syndromes in 200 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study compared 800 mg/day amisulpride and 20 mg/day haloperidol in patients with acute exacerbations of schizophrenia." | 9.08 | Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. ( Boyer, P; Fleurot, O; Möller, HJ; Rein, W, 1997) |
| "A 6-year-old severely handicapped boy with haloperidol-induced mild rhabdomyolysis without neuroleptic malignant syndrome is reported." | 8.80 | Haloperidol-induced rhabdomyolysis without neuroleptic malignant syndrome in a handicapped child. ( Abe, T; Oda, Y; Ozawa, K; Watanabe, T; Yoshikawa, H, 2000) |
| "Haloperidol treatment for 21 days impaired muscle co-ordination, motor activity and grip strength with an increased in orofacial dyskinetic movements." | 5.43 | Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation. ( Datta, S; Deshmukh, R; Jamwal, S; Kumar, P, 2016) |
| "Long-acting injectable risperidone was assessed in schizophrenia patients who were symptomatically stable on conventional depot antipsychotics and who were then switched to long-acting risperidone." | 5.11 | Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. ( Eerdekens, E; Eerdekens, M; Jacko, M; Turner, M, 2004) |
| " This study compared 800 mg/day amisulpride and 20 mg/day haloperidol in patients with acute exacerbations of schizophrenia." | 5.08 | Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. ( Boyer, P; Fleurot, O; Möller, HJ; Rein, W, 1997) |
| "A dopamine agonist (apomorphine) and a cholinomimetic drug (physostigmine) were administered to five patients with blepharospasm and oromandibular dystonia (Meige disease)." | 5.04 | Meige disease: striatal dopaminergic preponderance. ( Lai, C; Tolosa, ES, 1979) |
| "A 6-year-old severely handicapped boy with haloperidol-induced mild rhabdomyolysis without neuroleptic malignant syndrome is reported." | 4.80 | Haloperidol-induced rhabdomyolysis without neuroleptic malignant syndrome in a handicapped child. ( Abe, T; Oda, Y; Ozawa, K; Watanabe, T; Yoshikawa, H, 2000) |
| "This is a review of reserpine, haloperidol, and various phenothiazines that produce parkinsonism and other movement disorders." | 4.78 | Drug-induced parkinsonism and other movement disorders. ( Ross, RT, 1990) |
| "Haloperidol (Hal) is an antipsychotic related to movement disorders." | 3.91 | Influence of magnesium supplementation and L-type calcium channel blocker on haloperidol-induced movement disturbances. ( Burger, ME; da Silva Barcelos, RC; Kronbauer, M; Metz, VG; Milanesi, LH; Roversi, K; Rubert Rossato, D, 2019) |
| "Antipsychotic drugs have been used in the treatment of schizophrenia and their long-term use can cause movement disorders, such as tardive dyskinesia (TD) in humans mainly typical ones such as haloperidol." | 3.83 | Alteration of Cytokines Levels in the Striatum of Rats: Possible Participation in Vacuous Chewing Movements Induced by Antipsycotics. ( De Freitas, CM; Duarte, MM; Fachinetto, R; Ferrari, MC; Leal, CQ; Peroza, LR; Schaffer, LF, 2016) |
| "The undesired extrapyramidal movement disorders observed with long term treatment with haloperidol have been associated with striatal neurodegeneration." | 3.74 | Activation of striatal inflammatory mediators and caspase-3 is central to haloperidol-induced orofacial dyskinesia. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2008) |
| " The mothers of three infants had been on medication (either alpha-methyl dopa, reserpine or haloperidol) during pregnancy, whereas the mothers of the other three infants took no medication during pregnancy." | 3.71 | Rapid-eye-movement sleep in jittery infants. ( Iwakawa, Y; Kohyama, J; Shimohira, M, 2002) |
| "Although diphenhydramine hydrochloride is known to eliminate or reduce the symptoms of dystonia in human patients with acute dystonic reactions and idiopathic torsion dystonia, its mechanism of action is still unclear." | 3.69 | Evidence for the involvement of histamine in the antidystonic effects of diphenhydramine. ( Matsumoto, RR; Stone, MR; Truong, DD; van't Groenewout, JL; Vo, VN, 1995) |
| " SCH 23390 (a selective D1 antagonist) and raclopride (a selective D2 antagonist) induced identical syndromes consisting of dystonia and oral dyskinesia." | 3.67 | Selective D1 and D2 receptor manipulation in Cebus monkeys: relevance for dystonia and dyskinesia in humans. ( Gerlach, J; Kistrup, K, 1987) |
| "From among 1377 patients with movement disorders, four patients had an unusual movement disorder characterised by paroxysmal bursts of involuntary, regular, repetitive, rhythmic, bilateral, coordinated, simultaneous, stereotypic myoclonus and vocalisations, often associated with tonic symptoms, interference with voluntary functioning, presence of hyperactivity, attention and learning disabilities, and resistance to treatment with haloperidol and other drugs." | 3.67 | Paroxysmal myoclonic dystonia with vocalisations: new entity or variant of preexisting syndromes? ( Feinberg, TE; Shapiro, AK; Shapiro, E, 1986) |
| " Case 1 is a description of the subjective experience of a patient with acute orofacial dystonia from promethazine." | 3.66 | Case vignettes of movement disorders. ( Yung, CY, 1983) |
| "Acute dystonia can also be reliably induced in many primate species by neuroleptic treatment with comparable time course, symptomatology and pharmacological characteristics to those observed in man." | 2.37 | Acute dystonia induced by neuroleptic drugs. ( Jenner, P; Marsden, CD; Rupniak, NM, 1986) |
| "Haloperidol treatment for 21 days impaired muscle co-ordination, motor activity and grip strength with an increased in orofacial dyskinetic movements." | 1.43 | Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation. ( Datta, S; Deshmukh, R; Jamwal, S; Kumar, P, 2016) |
| "Tardive dyskinesia (TD) is a serious side effect induced by the long-term administration of typical antipsychotics." | 1.43 | Beneficial effects of EGb761 and vitamin E on haloperidol-induced vacuous chewing movements in rats: Possible involvement of S100B mechanisms. ( An, HM; Kosten, TR; Li, J; Lv, MH; Shi, J; Soares, JC; Tan, YL; Wang, YC; Wang, ZR; Yang, FD; Zhang, XY; Zhou, DF, 2016) |
| "Five haloperidol-treated animals developed mild TD movements, and no TD was observed in the clozapine group." | 1.40 | Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model. ( Blanchet, PJ; Lévesque, D; Mahmoudi, S, 2014) |
| "Five haloperidol-treated animals developed mild TD movements similar to those found in humans." | 1.39 | Haloperidol-induced striatal Nur77 expression in a non-human primate model of tardive dyskinesia. ( Blanchet, PJ; Lévesque, D; Mahmoudi, S, 2013) |
| " Oral dyskinesia was induced by chronic administration of haloperidol (1 mg/kg i." | 1.39 | Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia. ( Budhiraja, RD; Grover, S; Kumar, P; Singh, K; Vikram, V, 2013) |
| "Schizophrenia is thought to be the psychiatric diagnosis the most frequently associated with TD." | 1.39 | [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics]. ( Bellaaj, R; Bouguerra, C; Gallali, S; Mehdi, F; Oumaya, A; Sejil, I, 2013) |
| "Both haloperidol and nicotine treatment decreased the transporter and α6β2* nAChRs (the asterisk indicates the possible presence of other nicotinic subunits in the receptor complex) when given alone, with no further decline with combined drug treatment." | 1.38 | Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats. ( Bordia, T; McIntosh, JM; Quik, M, 2012) |
| "Here we used the animal models of extrapyramidal disorders cited above, which were performed in two distinct experiments: orofacial dyskinesia (OD)/catalepsy induced by acute reserpine and subchronic haloperidol after (experiment 1) and before (experiment 2) oral treatment with pecan shell aqueous extract (AE), a natural and promissory antioxidant." | 1.37 | Comparative study between two animal models of extrapyramidal movement disorders: prevention and reversion by pecan nut shell aqueous extract. ( Barcelos, RC; Benvegnú, DM; Boufleur, N; Bürger, ME; Dias, VT; Dolci, GS; Pase, CS; Reckziegel, P; Segat, HJ; Trevizol, F, 2011) |
| "A large cohort of 1528 patients with parkinsonism was analyzed, gathering data on demography, motor and non-motor characteristics, as well as the final etiologic diagnoses based on established criteria." | 1.36 | The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. ( Munhoz, RP; Teive, HA; Werneck, LC, 2010) |
| " Chronic administration of haloperidol (1 mg/kg i." | 1.35 | Co-administration of nitric oxide (NO) donors prevents haloperidol-induced orofacial dyskinesia, oxidative damage and change in striatal dopamine levels. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2009) |
| " Chronic administration of haloperidol (1 mg/kg, i." | 1.35 | Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2008) |
| " Chronic administration of haloperidol (1 mg/kg i." | 1.35 | Protective effect of L-type calcium channel blockers against haloperidol-induced orofacial dyskinesia: a behavioural, biochemical and neurochemical study. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2008) |
| "Haloperidol treatment produced VCM in 40% of the treated rats and the concomitant treatment with V." | 1.34 | Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter. ( Avila, DS; Burger, ME; Calixto, JB; Fachinetto, R; Ferreira, J; Pereira, RP; Rocha, JB; Villarinho, JG; Wagner, C, 2007) |
| "Hemiballismus is characterized by the abrupt onset of violent proximal flinging movements, affecting the limbs, neck and trunk on one side of the body." | 1.32 | Hemiballismus following general anesthesia. A case report. ( Buraczyńska, K; Pilarczyk, M; Sagan, M; Stelmasiak, Z; Tynecka, M, 2003) |
| "Haloperidol (HP) has been hypothesized to potentiate increases in oxidative stress or free radical-mediated levels of toxic metabolites in rat striatum while simultaneous upregulating dopamine (DA)-D2 receptors leading to presumed DA supersensitivity." | 1.32 | Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia. ( Fairfax, DF; Gupta, SK; Henry, P; Khan, RF; Mishra, RK; N-Marandi, S; Rogoza, RM, 2004) |
| "Low-amplitude, involuntary, choreiform movements involved the distal portions of these limbs." | 1.30 | Hemiballism-hemichorea from marked hypotension during spinal anesthesia. ( Itoh, H; Nitta, E; Shibata, K; Takamori, M, 1998) |
| " In contrast, increasing doses of amperozide resulted in decreasing vacuous jaw movements for this portion of the dose-response curve." | 1.30 | The effects of the atypical antipsychotic amperozide on vacuous jaw movements in rats: a novel dose response profile. ( Moser, L; Panos, J; Parret, F; Rutell, E; Steinpreis, RE, 1998) |
| "Treatment with haloperidol resulted in significantly more severe movement disorder in pinealectomized rats than in unoperated control rats." | 1.28 | Increased incidence and severity of neuroleptic-induced movement disorder in pinealectomized rats. ( Fisher, H; Sandyk, R, 1989) |
| "Rats with ablated frontal sensorimotor cortex and one with ablated sensorimotor connections to forebrain showed more vacuous chewing movements following 6-week chronic administration of a neuroleptic than did occipitally damaged rats or normal controls who were treated in the same way." | 1.26 | Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: implication for models of tardive dyskinesia. ( Glassman, HN; Glassman, RB, 1980) |
| "The syndrome was not seen after thioridazine (3-7 mg/kg)." | 1.26 | Acute dystonia as an idiosyncratic response to neuroleptics in baboons. ( Anlezark, GM; Marsden, CD; Meldrum, BS, 1977) |
| "Our results suggest that akinesia and catalepsy, induced in rats by haloperidol might be, at least in part, due to a decrease in sensitivity of alpha-motoneurones to proprioceptive stimuli." | 1.26 | Effect of haloperidol on reflex activation of rat alpha-motoneurones. A possible explanation for akinesia and catalepsy? ( Kuschinsky, K; Langer, J; Seeber, U; Sontag, KH, 1979) |
| "Pretreatment with haloperidole nullified the effect of apomorphine." | 1.26 | [Nigrostriatally induced motor reactions in the rat. I. Rotational behavior and posture asymetry after intracerebral injection of apomorphine and dopamine]. ( Staib, AH; Westermann, KH, 1976) |
| "Haloperidol was used in 12 patients in an attempt to improve l-dopa induced dyskinesias." | 1.25 | Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias. ( Klawans, HL; Weiner, WJ, 1974) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 128 (64.00) | 18.7374 |
| 1990's | 18 (9.00) | 18.2507 |
| 2000's | 20 (10.00) | 29.6817 |
| 2010's | 32 (16.00) | 24.3611 |
| 2020's | 2 (1.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wise, LD | 1 |
| Butler, DE | 1 |
| DeWald, HA | 1 |
| Lustgarten, D | 1 |
| Coughenour, LL | 1 |
| Downs, DA | 1 |
| Heffner, TG | 1 |
| Pugsley, TA | 1 |
| Rahi, V | 3 |
| Ram, P | 3 |
| Kumar, P | 5 |
| Syamkumar, S | 1 |
| Dossetor, D | 1 |
| Kronbauer, M | 1 |
| Metz, VG | 1 |
| Roversi, K | 1 |
| Milanesi, LH | 1 |
| Rubert Rossato, D | 1 |
| da Silva Barcelos, RC | 1 |
| Burger, ME | 5 |
| Mahmoudi, S | 2 |
| Blanchet, PJ | 2 |
| Lévesque, D | 2 |
| Reifsnyder, JW | 1 |
| Tettambel, MA | 1 |
| Grover, S | 1 |
| Singh, K | 1 |
| Vikram, V | 1 |
| Budhiraja, RD | 1 |
| Thakur, KS | 1 |
| Prakash, A | 2 |
| Bisht, R | 1 |
| Bansal, PK | 1 |
| Kinon, BJ | 1 |
| Kollack-Walker, S | 1 |
| Jeste, D | 1 |
| Gupta, S | 1 |
| Chen, L | 1 |
| Case, M | 1 |
| Chen, J | 1 |
| Stauffer, V | 1 |
| Yehl, JL | 1 |
| Sheyner, I | 1 |
| Fasnacht, KS | 1 |
| Stewart, JT | 1 |
| An, HM | 1 |
| Tan, YL | 1 |
| Shi, J | 1 |
| Wang, ZR | 1 |
| Li, J | 1 |
| Wang, YC | 1 |
| Lv, MH | 1 |
| Zhou, DF | 1 |
| Soares, JC | 1 |
| Kosten, TR | 1 |
| Yang, FD | 1 |
| Zhang, XY | 1 |
| Datta, S | 1 |
| Jamwal, S | 1 |
| Deshmukh, R | 1 |
| Peroza, LR | 1 |
| Schaffer, LF | 1 |
| De Freitas, CM | 1 |
| Leal, CQ | 1 |
| Ferrari, MC | 1 |
| Duarte, MM | 1 |
| Fachinetto, R | 3 |
| Bishnoi, M | 7 |
| Chopra, K | 6 |
| Kulkarni, SK | 6 |
| Barcelos, RC | 2 |
| Benvegnú, DM | 2 |
| Boufleur, N | 2 |
| Reckziegel, P | 2 |
| Müller, LG | 1 |
| Pase, C | 1 |
| Emanuelli, T | 1 |
| Luthra, PM | 1 |
| Barodia, SK | 1 |
| Kumari, R | 1 |
| Mishra, CB | 1 |
| Kumar, JB | 1 |
| Brown, AR | 1 |
| Hu, B | 1 |
| Antle, MC | 1 |
| Teskey, GC | 1 |
| Munhoz, RP | 1 |
| Werneck, LC | 1 |
| Teive, HA | 1 |
| Creed, M | 1 |
| Hamani, C | 3 |
| Nobrega, JN | 3 |
| Nade, VS | 1 |
| Kawale, LA | 1 |
| Yadav, AV | 1 |
| Kovacs, N | 1 |
| Herold, R | 1 |
| Janszky, J | 1 |
| Komoly, S | 1 |
| Nagy, F | 1 |
| Batool, F | 1 |
| Shah, AH | 1 |
| Ahmed, SD | 1 |
| Saify, ZS | 1 |
| Haleem, DJ | 1 |
| Giegling, I | 1 |
| Drago, A | 1 |
| Schäfer, M | 2 |
| Möller, HJ | 3 |
| Rujescu, D | 2 |
| Serretti, A | 1 |
| Glavina, T | 1 |
| Mrass, D | 1 |
| Dodig, T | 1 |
| Glavina, G | 1 |
| Pranić, S | 1 |
| Uglešić, B | 1 |
| Trevizol, F | 1 |
| Pase, CS | 1 |
| Segat, HJ | 1 |
| Dias, VT | 1 |
| Dolci, GS | 1 |
| Macêdo, DS | 2 |
| Oliveira, GV | 1 |
| Gomes, PX | 2 |
| Araújo, FY | 1 |
| Souza, CM | 1 |
| Vasconcelos, SM | 2 |
| Viana, GS | 1 |
| Sousa, FC | 1 |
| Carvalho, AF | 2 |
| Bordia, T | 1 |
| McIntosh, JM | 1 |
| Quik, M | 1 |
| Creed, MC | 2 |
| Boparai, RK | 1 |
| Chrisphonte, P | 1 |
| Ostroff, RB | 1 |
| Rosenheck, RA | 2 |
| Alencar, R | 1 |
| Camargos, S | 1 |
| Cardoso, T | 1 |
| Maia, D | 1 |
| Cardoso, F | 1 |
| Maxia, A | 1 |
| Frau, MA | 1 |
| Foddis, C | 1 |
| Lancioni, MC | 1 |
| Kasture, V | 1 |
| Kasture, S | 1 |
| Bachus, SE | 1 |
| Yang, E | 1 |
| McCloskey, SS | 1 |
| Minton, JN | 1 |
| Bridgman, A | 1 |
| Fletcher, PJ | 1 |
| de Oliveira, GV | 1 |
| de Araújo, FY | 1 |
| Júnior, HV | 1 |
| de Sousa, FC | 1 |
| de Lucena, DF | 1 |
| Hyphantis, TN | 1 |
| Su, CJ | 1 |
| Xu, XQ | 1 |
| Fan, Y | 1 |
| Du, RH | 1 |
| Hu, G | 1 |
| Sejil, I | 1 |
| Oumaya, A | 1 |
| Bouguerra, C | 1 |
| Mehdi, F | 1 |
| Bellaaj, R | 1 |
| Gallali, S | 1 |
| VAISBERG, M | 1 |
| SAUNDERS, JC | 1 |
| ALLEVA, PM | 1 |
| SABBATINI, F | 2 |
| HAEFNER, H | 1 |
| KUTSCHER, I | 1 |
| MARQUEZ, C | 1 |
| GAGO, MI | 1 |
| LUCIANO, M | 1 |
| LAGOCKI, AM | 1 |
| PASQUALINI, G | 1 |
| QUINCI, A | 1 |
| SARADJIEFF, P | 1 |
| SHYSTER, M | 1 |
| LURIA, E | 1 |
| RIZZUTO, N | 1 |
| LUNA, NE | 1 |
| NAYRAC, P | 1 |
| ARNOTT, G | 1 |
| MILBLED, G | 1 |
| Faurbye, A | 1 |
| Clausen, J | 1 |
| Pilarczyk, M | 1 |
| Buraczyńska, K | 1 |
| Sagan, M | 1 |
| Tynecka, M | 1 |
| Stelmasiak, Z | 1 |
| Grande, C | 1 |
| Zhu, H | 1 |
| Martin, AB | 1 |
| Lee, M | 1 |
| Ortiz, O | 1 |
| Hiroi, N | 1 |
| Moratalla, R | 1 |
| Henkel, V | 1 |
| Mergl, R | 1 |
| Hegerl, U | 1 |
| Turner, M | 2 |
| Eerdekens, E | 1 |
| Jacko, M | 1 |
| Eerdekens, M | 1 |
| Rogoza, RM | 1 |
| Fairfax, DF | 1 |
| Henry, P | 1 |
| N-Marandi, S | 1 |
| Khan, RF | 1 |
| Gupta, SK | 1 |
| Mishra, RK | 1 |
| Kovoor, A | 1 |
| Seyffarth, P | 1 |
| Ebert, J | 1 |
| Barghshoon, S | 1 |
| Chen, CK | 1 |
| Schwarz, S | 1 |
| Axelrod, JD | 1 |
| Cheyette, BN | 1 |
| Simon, MI | 1 |
| Lester, HA | 1 |
| Schwarz, J | 1 |
| Villarinho, JG | 1 |
| Wagner, C | 1 |
| Pereira, RP | 2 |
| Avila, DS | 1 |
| Calixto, JB | 1 |
| Rocha, JB | 2 |
| Ferreira, J | 1 |
| Archer, T | 1 |
| Fredriksson, A | 1 |
| Colpo, G | 1 |
| Trevisol, F | 1 |
| Teixeira, AM | 1 |
| Athayde, ML | 1 |
| Lapolla, A | 1 |
| Glassman, RB | 1 |
| Glassman, HN | 1 |
| Neale, R | 1 |
| Gerhardt, S | 1 |
| Fallon, S | 1 |
| Liebman, JM | 2 |
| Barbeau, A | 2 |
| Rondeau, DB | 1 |
| Jolicoeur, FB | 1 |
| Chesire, RM | 1 |
| Cheng, JT | 1 |
| Teitelbaum, P | 1 |
| Puca, FM | 1 |
| Minervini, MG | 1 |
| Savarese, M | 1 |
| Quarta, F | 1 |
| De Marzo, C | 1 |
| Lanave, C | 1 |
| Emre, M | 1 |
| Landis, T | 1 |
| Yung, CY | 1 |
| Patti, F | 1 |
| Giammona, G | 1 |
| Rampello, L | 1 |
| Reggio, A | 1 |
| Gallitto, G | 1 |
| Nicoletti, F | 1 |
| Bédard, P | 2 |
| Boucher, R | 3 |
| Di Paolo, T | 1 |
| Labrie, F | 1 |
| Boschi, G | 1 |
| Launay, N | 1 |
| Rips, R | 1 |
| Lodder, J | 1 |
| Baard, WC | 1 |
| Coulter, DL | 1 |
| Donofrio, P | 1 |
| van't Groenewout, JL | 1 |
| Stone, MR | 1 |
| Vo, VN | 1 |
| Truong, DD | 1 |
| Matsumoto, RR | 1 |
| Sakharov, D | 1 |
| Voronezhskaya, E | 1 |
| Nezlin, L | 1 |
| Gerrard, JW | 1 |
| Richardson, JS | 1 |
| Donat, J | 1 |
| Khanna, R | 1 |
| Damodaran, SS | 1 |
| Chakraborty, SP | 1 |
| Hanaoka, Y | 1 |
| Ohi, T | 1 |
| Matsukura, S | 1 |
| Andreassen, OA | 1 |
| Aamo, TO | 1 |
| Jøorgensen, HA | 1 |
| Fang, J | 1 |
| Baker, GB | 1 |
| Silverstone, PH | 1 |
| Coutts, RT | 1 |
| Georgiou, N | 1 |
| Phillips, JG | 1 |
| Bradshaw, JL | 1 |
| Cunnington, R | 1 |
| Chiu, E | 1 |
| Boyer, P | 1 |
| Fleurot, O | 1 |
| Rein, W | 1 |
| Bashir, K | 1 |
| Manyam, BV | 1 |
| Vila, N | 1 |
| Chamorro, A | 1 |
| Itoh, H | 1 |
| Shibata, K | 1 |
| Nitta, E | 1 |
| Takamori, M | 1 |
| Steinpreis, RE | 1 |
| Moser, L | 1 |
| Parret, F | 1 |
| Rutell, E | 1 |
| Panos, J | 1 |
| Miwa, H | 1 |
| Nishi, K | 1 |
| Fuwa, T | 1 |
| Mizuno, Y | 1 |
| Yoshikawa, H | 1 |
| Watanabe, T | 1 |
| Abe, T | 1 |
| Oda, Y | 1 |
| Ozawa, K | 1 |
| Shimohira, M | 1 |
| Iwakawa, Y | 1 |
| Kohyama, J | 1 |
| Weitzman, DO | 1 |
| Rosfnfeld, C | 1 |
| Korenyl, C | 1 |
| Whittier, JR | 1 |
| Tolosa, ES | 2 |
| Calne, DB | 1 |
| Eisler, T | 1 |
| Goldstein, M | 1 |
| Battista, AF | 1 |
| Miyamoto, T | 1 |
| Marais, C | 1 |
| Van Praag, HM | 1 |
| Korf, J | 1 |
| Godwin-Austen, RB | 1 |
| Lai, C | 1 |
| Meldrum, BS | 1 |
| Anlezark, GM | 1 |
| Marsden, CD | 4 |
| Weiss, B | 1 |
| Santelli, S | 1 |
| Lusink, G | 1 |
| Pappenheim, E | 1 |
| Morselli, PL | 1 |
| Bianchetti, G | 1 |
| Durand, G | 1 |
| Le Heuzey, MF | 1 |
| Zarifian, E | 1 |
| Dugas, M | 1 |
| Cerbo, R | 1 |
| Carchedi, F | 1 |
| Casacchia, M | 1 |
| Meco, G | 1 |
| Langer, J | 1 |
| Seeber, U | 1 |
| Kuschinsky, K | 1 |
| Sontag, KH | 1 |
| Extein, I | 1 |
| Ule, G | 1 |
| Struwe, O | 1 |
| Frangos, E | 1 |
| Christodoulides, H | 1 |
| Gunne, LM | 1 |
| Bárány, S | 1 |
| Gilden, DH | 1 |
| Davis, MJ | 1 |
| Klawans, HL | 4 |
| Moses, H | 1 |
| Nausieda, PA | 1 |
| Bergen, D | 1 |
| Weiner, WJ | 3 |
| Westermann, KH | 1 |
| Staib, AH | 1 |
| Gilbert, GJ | 2 |
| Sayers, AC | 2 |
| Bürki, HR | 2 |
| Gerlach, J | 2 |
| Thorsen, K | 1 |
| Fog, R | 1 |
| Moline, RA | 1 |
| Dankova, J | 1 |
| Poirier, LJ | 3 |
| Cools, AR | 1 |
| Hendriks, G | 1 |
| Korten, J | 1 |
| Ruch, W | 1 |
| Asper, H | 1 |
| Tegtmeyer, GF | 1 |
| Stimmel, GL | 1 |
| Clyne, KE | 1 |
| Juhl, R | 1 |
| Boukthir, S | 1 |
| Trabelsi, M | 1 |
| Sammoud, S | 1 |
| Hammou-Jeddi, A | 1 |
| Touibi, S | 1 |
| Bennaceur, B | 1 |
| Decina, P | 1 |
| Caracci, G | 1 |
| Scapicchio, PL | 1 |
| Ross, RT | 1 |
| Rupniak, NM | 2 |
| Tye, SJ | 1 |
| Steventon, MJ | 1 |
| Boyce, S | 1 |
| Iversen, SD | 1 |
| Gerhardt, SC | 1 |
| Gerber, R | 1 |
| Weihmuller, FB | 2 |
| Hadjiconstantinou, M | 2 |
| Bruno, JP | 2 |
| Neff, NH | 2 |
| Sandyk, R | 1 |
| Fisher, H | 1 |
| Jenner, P | 2 |
| Aksent'ev, SB | 1 |
| Borisova, NP | 1 |
| Levinskiĭ, MV | 1 |
| Kryzhanovskiĭ, GN | 1 |
| Kistrup, K | 1 |
| Bruun, RD | 2 |
| Caine, ED | 1 |
| McBride, MC | 1 |
| Chiverton, P | 1 |
| Bamford, KA | 1 |
| Rediess, S | 1 |
| Shiao, J | 1 |
| Feinberg, TE | 1 |
| Shapiro, AK | 3 |
| Shapiro, E | 2 |
| Colpaert, FC | 1 |
| Browne, JL | 1 |
| Hart, RR | 1 |
| Rasmussen, D | 1 |
| Hoogstraten, MC | 1 |
| Lakke, JP | 1 |
| Zwarts, MJ | 1 |
| Horikawa, H | 1 |
| Konagaya, M | 1 |
| Mano, Y | 1 |
| Takayanagi, T | 1 |
| Ekbom, K | 1 |
| Lindholm, H | 1 |
| Ljungberg, L | 1 |
| Gessa, R | 1 |
| Tagliamonte, A | 1 |
| Gessa, GL | 1 |
| McCaul, JA | 1 |
| Stern, GM | 1 |
| Mowat, AP | 1 |
| Kiloh, LG | 1 |
| Smith, JS | 1 |
| Williams, SE | 1 |
| Niturad, A | 1 |
| Ciurezu, T | 1 |
| Cucu, I | 1 |
| Langelier, P | 1 |
| Larochelle, L | 1 |
| Parent, A | 1 |
| Roberge, AG | 1 |
| Kivalo, E | 2 |
| Weckman, N | 2 |
| Ungerstedt, U | 1 |
| Dill, RE | 1 |
| Chase, TN | 1 |
| Divac, I | 1 |
| Turunen, S | 1 |
| Achté, KA | 1 |
| Semanovskaia, EI | 1 |
| Bordeleau, JM | 1 |
| Tétreault, L | 1 |
| Marhold, J | 1 |
| Zimanová, J | 1 |
| Lachman, M | 1 |
| Král, J | 1 |
| Vojtĕchovský, M | 1 |
| Rosin, AJ | 1 |
| Hale, MS | 1 |
| Cohen, WJ | 1 |
| Cohen, NH | 1 |
| Wayne, H | 1 |
| Kazamatsuri, H | 2 |
| Chien, C | 1 |
| Cole, JO | 2 |
| Singh, MM | 1 |
| Di Scipio, WJ | 1 |
| Chien, CP | 1 |
| Ijima, M | 1 |
| Harada, M | 1 |
| Hatano, M | 1 |
| Goto, N | 1 |
| Ayd, FJ | 1 |
| Lien, EJ | 1 |
| Gudauskas, GA | 1 |
| Crane, GE | 1 |
| Simpson, MA | 1 |
| Jacobson, G | 1 |
| Baldessarini, RJ | 1 |
| Manschreck, T | 1 |
| Bhaskar, PA | 1 |
| Jagannathan, K | 1 |
| Dolphin, A | 1 |
| Duvoisin, RC | 1 |
| Tarsy, D | 1 |
| Gallant, DM | 1 |
| Bishop, M | 1 |
| Guerrero-Figueroa, R | 1 |
| Mattke, DJ | 1 |
| Edmonds-Seal, J | 1 |
| Prys-Roberts, C | 1 |
| Simpson, GM | 1 |
| Angus, JW | 1 |
| Dom, R | 1 |
| Van Lommel, R | 1 |
| Baro, F | 1 |
| McKendall, RR | 1 |
| Challas, G | 1 |
| Chapel, JL | 1 |
| Jenkins, RL | 1 |
| Goldstein, S | 1 |
| Himwich, WA | 1 |
| Leiner, K | 1 |
| Stout, M | 1 |
| Demars, JP | 1 |
| Castaigne, P | 1 |
| Lapresle, J | 1 |
| Chain, F | 1 |
| Radzuweit, H | 1 |
| Knorr, W | 1 |
| Gurovich, IIa | 1 |
| Fleĭs, EP | 1 |
| Malm, U | 1 |
| Mandell, S | 1 |
| Insua, JA | 1 |
| Agúe, C | 1 |
| Glatzel, J | 1 |
| Salvini, L | 1 |
| Frosali, L | 1 |
| Gigli, M | 1 |
| Hezar-Khani, F | 1 |
| Vogelberg, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Blood Lactate Levels in Patients Treated With Typical or Atypical Antipsychotics[NCT01139463] | 60 participants (Actual) | Observational | 2008-06-30 | Completed | |||
| Behavior Therapy and Psychosocial Treatment for Tourette Syndrome and Chronic Tic Disorder[NCT00231985] | Phase 2 | 122 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| TRANSCRANIAL DIRECT CURRENT STIMULATION (t-DCS) AS ADD-ON TO NEUROREHABILITATION OF PISA SYNDROME IN PARKINSON DISEASE: A RANDOMIZED CONTROLLED TRIAL[NCT04620863] | 30 participants (Actual) | Interventional | 2019-01-15 | Completed | |||
| Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone[NCT00096863] | Phase 2 | 102 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| The Effects of Glycine Transport Inhibition on Brain Glycine Concentration[NCT00538070] | 68 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| The Relationship Between the Efficacy of Lumateperone and Central Glutamate and Dopaminergic Metabolism: A Comparison With Risperidone in First Episode Psychosis[NCT05890768] | Phase 4 | 35 participants (Anticipated) | Interventional | 2023-05-11 | Recruiting | ||
| Alterations in mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) of Schizophrenia Patients Treated With Fluvoxamine Augmentation of Antipsychotics: Relationship to Clinical Symptoms and Cognitive Function[NCT00645580] | 15 participants (Anticipated) | Interventional | 2008-04-30 | Active, not recruiting | |||
| Identification, Assessment, and Treatment of Tardive Dyskinesia With Valbenazine in Adults With Intellectual/Developmental Disabilities and Co-occurring Psychiatric and/or Behavioral Disorders[NCT06107829] | Phase 4 | 25 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
12 reviews available for haloperidol and Dyskinesia Syndromes
| Article | Year |
|---|---|
[COMPLICATIONS DURING CLINICAL THERAPY WITH PSYCHOPHARMACA].
Topics: Agranulocytosis; Autonomic Nervous System Diseases; Chemical and Drug Induced Liver Injury; Chlorpro | 1964 |
Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator.
Topics: Antipsychotic Agents; Cholinergic Antagonists; Clinical Trials as Topic; Depression; Female; Haloper | 2005 |
Behavioral effects of substance P in rats.
Topics: Animals; Behavior, Animal; Dose-Response Relationship, Drug; Grooming; Haloperidol; Injections, Intr | 1980 |
[Ballism, hemiballism].
Topics: Cerebrovascular Disorders; Chlorpromazine; Electromyography; Haloperidol; Humans; Movement Disorders | 1993 |
Haloperidol-induced rhabdomyolysis without neuroleptic malignant syndrome in a handicapped child.
Topics: Anti-Dyskinesia Agents; Child; Disabled Persons; Haloperidol; Humans; Male; Movement Disorders; Neur | 2000 |
The pathogensis and medical treatment of extrapyramidal disease.
Topics: Adult; Athetosis; Basal Ganglia Diseases; Caudate Nucleus; Chorea; Corpus Striatum; Dopamine; Dopami | 1979 |
[Duality of dopaminergic receptors. Pharmacologic and clinical perspectives].
Topics: Animals; Apomorphine; Benzamides; Chorea; Fluorescent Antibody Technique; Guinea Pigs; Haloperidol; | 1978 |
Drug-induced parkinsonism and other movement disorders.
Topics: Haloperidol; Humans; Movement Disorders; MPTP Poisoning; Parkinson Disease, Secondary; Phenothiazine | 1990 |
Acute dystonia induced by neuroleptic drugs.
Topics: Acute Disease; alpha-Methyltyrosine; Animals; Antipsychotic Agents; Brain; Chlorpromazine; Disease M | 1986 |
Nervous mechanisms involved in experimentally induced extrapyramidal disturbances.
Topics: Animals; Basal Ganglia Diseases; Benztropine; Brain; Cats; Caudate Nucleus; Cerebellar Nuclei; Chlor | 1974 |
Drug-induced extrapyramidal disorders.
Topics: Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Benztropine; Dihydroxyphenylalanine; Dopa | 1972 |
Pharmacology of drugs used in neuroleptanalgesia.
Topics: Aminobutyrates; Anesthesia, General; Animals; Benperidol; Butyrophenones; Cell Membrane Permeability | 1970 |
17 trials available for haloperidol and Dyskinesia Syndromes
| Article | Year |
|---|---|
Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Female; Halo | 2015 |
Blood lactate levels in patients receiving first- or second- generation antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dopamine Antagonists; Drug Monitoring; Haloperidol; Hu | 2011 |
Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response Relationship, | 2004 |
Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group.
Topics: Adult; Akathisia, Drug-Induced; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; D | 1997 |
Studies on the anti-dyskinesia effect of apomorphine in man.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Clinical Trials as Topic; Drug Evaluation; Female; H | 1976 |
Meige disease: striatal dopaminergic preponderance.
Topics: Aged; Apomorphine; Basal Ganglia; Blepharospasm; Clinical Trials as Topic; Diagnosis, Differential; | 1979 |
Clinical observations of the treatment of tardive dyskinesia with haloperidol.
Topics: Adult; Antiparkinson Agents; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Middle Age | 1975 |
Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients.
Topics: Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Clozapine; Dibenzazepines; Haloperido | 1975 |
Letter: Lithium and haloperidol in movement disorders.
Topics: Administration, Oral; Adult; Aged; Carbonates; Clinical Trials as Topic; Drug Tolerance; Haloperidol | 1974 |
Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate.
Topics: Adult; Aged; Basal Ganglia Diseases; Brain Chemistry; Clinical Trials as Topic; Dopamine; Evaluation | 1972 |
Changes in staff anxiety and attitudes during a double blind study of haloperidol in acute schizophrenics within a structured milieu.
Topics: Antiparkinson Agents; Anxiety; Attitude of Health Personnel; Benztropine; Clinical Trials as Topic; | 1972 |
Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine.
Topics: Adult; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Evaluatio | 1973 |
Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action.
Topics: Acute Disease; Antidepressive Agents; Chlorpromazine; Clinical Trials as Topic; Haloperidol; Humans; | 1967 |
A pilot investigation in neuroleptic therapy.
Topics: Adult; Autonomic Nervous System; Clinical Trials as Topic; Female; Haloperidol; Handwriting; Humans; | 1968 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A rating scale for extrapyramidal side effects.
Topics: Clinical Trials as Topic; Extrapyramidal Tracts; Haloperidol; Humans; Motor Activity; Movement Disor | 1970 |
A quantitative study of neuroleptic-induced extrapyramidal symptoms and their response to dexetimide, a potent and long-acting antiparkinsonian agent.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Basal Ganglia Diseases; Benztropine; Benzyl Compo | 1971 |
Neuromuscular effects of long-term phenothiazine medication, electroconvulsive therapy and leucotomy.
Topics: Aged; Chlorpromazine; Clinical Trials as Topic; Electric Stimulation Therapy; Female; Haloperidol; H | 1966 |
171 other studies available for haloperidol and Dyskinesia Syndromes
| Article | Year |
|---|---|
(5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Apomorphine; Ataxia; Avoidance Learning; Brain; Cebus; Chemical Pheno | 1986 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Severe movement disorder and psychosis from haloperidol withdrawal in a 7-year-old girl with autism.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Female; Haloperidol; Humans; Movement Disorders; Psy | 2021 |
Influence of magnesium supplementation and L-type calcium channel blocker on haloperidol-induced movement disturbances.
Topics: Animals; Antipsychotic Agents; Brain; Calcium Channel Blockers; Calcium Channels, L-Type; Corpus Str | 2019 |
Haloperidol-induced striatal Nur77 expression in a non-human primate model of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Cebus; Clozapine; Corpus Striatum; Female; Haloperidol; Movement Diso | 2013 |
Conservative approach to tardive dyskinesia-induced neck and upper back pain.
Topics: Adult; Antipsychotic Agents; Back Pain; Female; Haloperidol; Humans; Manipulation, Osteopathic; Move | 2013 |
Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Disease Models, Animal; Fenofibrate; H | 2013 |
Beneficial effect of candesartan and lisinopril against haloperidol-induced tardive dyskinesia in rat.
Topics: Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Body Weight; Grooming; Haloperidol; Hand | 2015 |
Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.
Topics: Animals; Antipsychotic Agents; Brain; Cebus; Clozapine; Disease Models, Animal; Dopamine Antagonists | 2014 |
A case of tardive dyskinesia in the last weeks of life.
Topics: Anti-Dyskinesia Agents; Chlorpromazine; Haloperidol; Hiccup; Hospice Care; Humans; Male; Middle Aged | 2015 |
Beneficial effects of EGb761 and vitamin E on haloperidol-induced vacuous chewing movements in rats: Possible involvement of S100B mechanisms.
Topics: Animals; Anti-Dyskinesia Agents; Brain; Disease Models, Animal; Drug Evaluation, Preclinical; Ginkgo | 2016 |
Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Antipsychotic Agents; Behavior, Animal; Carotenoids | 2016 |
Alteration of Cytokines Levels in the Striatum of Rats: Possible Participation in Vacuous Chewing Movements Induced by Antipsycotics.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Corpus Striatum; Cytokines; Haloperidol; Male; Move | 2016 |
Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Dopamine; Dyskinesia, Drug-Induced; Haloperidol; Ma | 2008 |
Activation of striatal inflammatory mediators and caspase-3 is central to haloperidol-induced orofacial dyskinesia.
Topics: Animals; Antipsychotic Agents; Caspase 3; Corpus Striatum; Dose-Response Relationship, Drug; Dyskine | 2008 |
Co-administration of nitric oxide (NO) donors prevents haloperidol-induced orofacial dyskinesia, oxidative damage and change in striatal dopamine levels.
Topics: Animals; Antipsychotic Agents; Arginine; Chromatography, High Pressure Liquid; Citrulline; Dopamine; | 2009 |
Effects of omega-3 essential fatty acids (omega-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Disease Models, An | 2010 |
In silico study of naphtha [1, 2-d] thiazol-2-amine with adenosine A 2A receptor and its role in antagonism of haloperidol-induced motor impairments in mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Corpus Striatum; Dopamine; Haloperidol; Humans; Male; Mi | 2009 |
Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopam | 2009 |
The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics.
Topics: Aged; Antipsychotic Agents; Cinnarizine; Cohort Studies; Diagnosis, Differential; Female; Flunarizin | 2010 |
Deep brain stimulation of the subthalamic or entopeduncular nucleus attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.
Topics: Animals; Deep Brain Stimulation; Disease Models, Animal; Entopeduncular Nucleus; Exploratory Behavio | 2011 |
Protective effect of Morus alba leaves on haloperidol-induced orofacial dyskinesia and oxidative stress.
Topics: Animals; Dyskinesia, Drug-Induced; Haloperidol; Lipid Peroxidation; Male; Morus; Movement Disorders; | 2010 |
Tics status: a movement disorder emergency: observations.
Topics: Adolescent; Antipsychotic Agents; Clonazepam; Creatine Kinase; Diagnostic and Statistical Manual of | 2011 |
Protective effects of aqueous fruit extract from Sea Buckthorn (Hippophae rhamnoides L. Spp. Turkestanica) on haloperidol-induced orofacial dyskinesia and neuronal alterations in the striatum.
Topics: Administration, Oral; Animals; Catalepsy; Dopamine; Exploratory Behavior; Fruit; Haloperidol; Hippop | 2010 |
Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects.
Topics: Adult; Antipsychotic Agents; Demography; Drug Administration Schedule; Female; Haloperidol; Humans; | 2011 |
Comparative study between two animal models of extrapyramidal movement disorders: prevention and reversion by pecan nut shell aqueous extract.
Topics: Animals; Basal Ganglia Diseases; Carya; Catalepsy; Disease Models, Animal; Haloperidol; Male; Moveme | 2011 |
B vitamins attenuate haloperidol-induced orofacial dyskinesia in rats: possible involvement of antioxidant mechanisms.
Topics: Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Drug Therapy, Combination; Dyskinesia | 2011 |
Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dopamine Plasma Membrane Transport Protei | 2012 |
Early gene mapping after deep brain stimulation in a rat model of tardive dyskinesia: comparison with transient local inactivation.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Deep Brain Stimulation; Early Growth Response P | 2012 |
An animal model to study the molecular basis of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Apoptosis; Behavior, Animal; Caspase 3; Clozapine; Disease Models, An | 2012 |
Perphenazine suspension: a new, old treatment, side effects and continuous use.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Clinical Trials as Topic; Dru | 2012 |
Jumpy stump triggered by tardive dyskinesia.
Topics: Aged; Amputation Stumps; Amputation, Surgical; Antipsychotic Agents; Haloperidol; Humans; Leg; Male; | 2013 |
Ethanolic extract of Rubia peregrina L. (Rubiaceae) inhibits haloperidol-induced catalepsy and reserpine-induced orofacial dyskinesia.
Topics: Animals; Catalepsy; Ethanol; Haloperidol; Male; Movement Disorders; Plant Extracts; Rats; Reserpine; | 2012 |
Parallels between behavioral and neurochemical variability in the rat vacuous chewing movement model of tardive dyskinesia.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Autoradiography; Behavior, A | 2012 |
Contribution of decreased serotonin release to the antidyskinetic effects of deep brain stimulation in a rodent model of tardive dyskinesia: comparison of the subthalamic and entopeduncular nuclei.
Topics: 5,7-Dihydroxytryptamine; Amphetamines; Analysis of Variance; Animals; Antipsychotic Agents; Autoradi | 2012 |
Prevention of haloperidol-induced alterations in brain acetylcholinesterase activity by vitamins B co-administration in a rodent model of tardive dyskinesia.
Topics: Acetylcholinesterase; Animals; Antipsychotic Agents; Brain; Haloperidol; Male; Movement Disorders; R | 2013 |
Aquaporin-4 knockout abolishes apomorphine-induced tardive dyskinesia following chronic treatment with neuroleptics.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Aquaporin 4; | 2012 |
[Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
Topics: Adult; Antipsychotic Agents; Cross-Sectional Studies; Delayed-Action Preparations; Dose-Response Rel | 2013 |
TREATMENT OF DYSKINESIAS INCLUDING HUNTINGTON'S CHOREA WITH THIOPROPAZATE AND R-1625.
Topics: Chorea; Dyskinesias; Haloperidol; Humans; Huntington Disease; Movement Disorders; Phenothiazines; Tr | 1963 |
[AKINETON IN PARKINSONISM CAUSED BY DRUGS].
Topics: Anti-Allergic Agents; Biperiden; Haloperidol; Histamine H1 Antagonists; Movement Disorders; Neurolog | 1963 |
[THE NEUROTROPIC SIDE-EFFECTS OF BUTYRROPHENONES].
Topics: Haloperidol; Humans; Movement Disorders; Nervous System; Parkinsonian Disorders; Pharmacology; Toxic | 1964 |
[CLINICO-PSYCHIATRIC EXPERIMENTATION WITH HALOPERIDOL].
Topics: Biomedical Research; Haloperidol; Mental Disorders; Movement Disorders; Salivation; Sleep Initiation | 1964 |
[THE BUTYROPHENONE DERIVATIVES].
Topics: Alcoholism; Antipsychotic Agents; Haloperidol; Humans; Intellectual Disability; Ketones; Mental Diso | 1964 |
[CONTRIBUTION TO THE STUDY OF A NEURODYSLEPTIC SYNDROME IN THE COURSE OF HALOPERIDOL THERAPY].
Topics: Antisocial Personality Disorder; Drug Therapy; Extrapyramidal Tracts; Haloperidol; Mental Disorders; | 1964 |
[TREATMENT OF CHRONIC PSYCHOSES WITH HALOPERIDOL (R 1625)].
Topics: Bipolar Disorder; Drug Therapy; Haloperidol; Humans; Mental Disorders; Movement Disorders; Psychotic | 1964 |
[HUNTINGTON'S CHOREA, TEMPERAMENT DISORDERS OF MANIAC EXPRESSION. BENEFICIAL EFFECTS OF HALOPERIDOL (FLUORO-PHENYL-PIPERIDINE BUTYROPHENONE). ABSENCE OF THE THERAPEUTIC AKINETO-HYPERTONIC SYNDROME].
Topics: Bipolar Disorder; Butyrophenones; Chorea; Drug Therapy; Electromyography; Haloperidol; Humans; Hunti | 1964 |
CHANGES IN SERUM PROTEINS AND CEREBROSPINAL FLUID PROTEINS DURING PHARMACOTHERAPY OF PSYCHOSES.
Topics: Alcoholism; Bipolar Disorder; Blood Proteins; Cerebrospinal Fluid Proteins; Chlorpromazine; Drug The | 1964 |
Hemiballismus following general anesthesia. A case report.
Topics: Anesthesia, General; Anticonvulsants; Antipsychotic Agents; Brain Ischemia; Clonazepam; Dyskinesias; | 2003 |
Chronic treatment with atypical neuroleptics induces striosomal FosB/DeltaFosB expression in rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Caudate Nucleus; Clozapine; Drug Administration Sche | 2004 |
Kinematical analysis of motor function in schizophrenic patients: a possibility to separate negative symptoms from extrapyramidal dysfunction induced by neuroleptics?
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Biomechanical Phenomena; Butyrophenones; Case-C | 2004 |
Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Binding Sites; C | 2004 |
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Antipsych | 2005 |
Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter.
Topics: Animals; Antipsychotic Agents; Anxiety; Behavior, Animal; Brain Chemistry; Dopamine; Dopamine Antago | 2007 |
Functional consequences of iron overload in catecholaminergic interactions: the Youdim factor.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Brain Chemistry; Catecholamines; Clozapine; Denerva | 2007 |
Ilex paraguariensis has antioxidant potential and attenuates haloperidol-induced orofacial dyskinesia and memory dysfunction in rats.
Topics: Animals; Antioxidants; Behavior, Animal; Haloperidol; Ilex paraguariensis; In Vitro Techniques; Male | 2007 |
Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
Topics: Animals; Antipsychotic Agents; Brain Diseases; Control Groups; Disease Models, Animal; Dopamine; Dys | 2008 |
U-74500A (lazaroid), a 21-aminosteroid attenuates neuroleptic-induced orofacial dyskinesia.
Topics: Animals; Antioxidants; Antipsychotic Agents; Chlorpromazine; Disease Models, Animal; Dyskinesia, Dru | 2007 |
Protective effect of L-type calcium channel blockers against haloperidol-induced orofacial dyskinesia: a behavioural, biochemical and neurochemical study.
Topics: Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Calcium Channel Blockers; Calcium Cha | 2008 |
Clinical efficacy of haloperidol in chronic psychotic patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Female; Haloperidol; Humans; Male; Middle A | 1967 |
Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: implication for models of tardive dyskinesia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Brain; Chlorpromazine; Di | 1980 |
Progressive changes in the acute dyskinetic syndrome as a function of repeated elicitation in squirrel monkeys.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Benztropine; Drug Tolerance; Ha | 1982 |
Reversal of akinesia and release of festination by morphine or GABA applied focally to the nucleus reticularis tegmenti pontis.
Topics: Animals; Depression, Chemical; gamma-Aminobutyric Acid; Haloperidol; Male; Morphine; Movement Disord | 1984 |
[Sleep in a case of hemiballism].
Topics: Aged; Electroencephalography; Female; Haloperidol; Humans; Ischemia; Movement Disorders; Sleep Stage | 1984 |
Haloperidol in hemichorea-hemiballismus.
Topics: Aged; Chorea; Female; Haloperidol; Humans; Movement Disorders | 1984 |
Case vignettes of movement disorders.
Topics: Adult; Amantadine; Brain Injuries; Clonazepam; Diagnosis, Differential; Dystonia; Female; Haloperido | 1983 |
Antidyskinetic properties of estrogens.
Topics: Animals; Apomorphine; Catalepsy; Estradiol; Estrogens; Glutamate Decarboxylase; Haloperidol; Humans; | 1983 |
Interaction between estradiol, prolactin, and striatal dopaminergic mechanisms.
Topics: Animals; Corpus Striatum; Domperidone; Dopamine; Estradiol; Female; Haloperidol; Macaca fascicularis | 1984 |
Induction of wet-dog shakes by intracerebral 'acid' TRH in rats.
Topics: Animals; Apomorphine; Cyproheptadine; Dose-Response Relationship, Drug; Haloperidol; Injections, Int | 1980 |
Paraballism caused by bilateral hemorrhagic infarction in basal ganglia.
Topics: Aged; Basal Ganglia Diseases; Caudate Nucleus; Cerebral Hemorrhage; Cerebral Infarction; Female; Hal | 1981 |
Haloperidol for nonkinesiogenic paroxysmal dyskinesia.
Topics: Adult; Carbamazepine; Haloperidol; Humans; Male; Movement Disorders | 1980 |
Evidence for the involvement of histamine in the antidystonic effects of diphenhydramine.
Topics: Animals; Diphenhydramine; Disease Models, Animal; Dose-Response Relationship, Drug; Dystonia; Halope | 1995 |
Chronic haloperidol: neural correlates of motor disorders in an invertebrate model.
Topics: Animals; Catecholamines; Disease Models, Animal; Dopamine; Fluorescence; Glyoxylates; Haloperidol; H | 1994 |
Neuropharmacological evaluation of movement disorders that are adverse reactions to specific foods.
Topics: Adult; Animals; Aspartame; Carbidopa; Coffee; Diazepam; Double-Blind Method; Eggs; Female; Food Hype | 1994 |
Overflow movements may predict neuroleptic-induced dystonia.
Topics: Adolescent; Adult; Bipolar Disorder; Dyskinesia, Drug-Induced; Dystonia; Haloperidol; Humans; Male; | 1994 |
Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats.
Topics: Animals; Female; Haloperidol; Memantine; Movement Disorders; Rats; Rats, Sprague-Dawley | 1996 |
Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol.
Topics: Biotransformation; Cell Line; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzy | 1997 |
Impairments of movement kinematics in patients with Huntington's disease: a comparison with and without a concurrent task.
Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Dyskinesia Agents; Anticonvulsants; Clonazepam; Dothiepin; | 1997 |
Clozapine for the control of hemiballismus.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Clozapine; Haloperidol; Humans; Hypnotics and Sedative | 1994 |
Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.
Topics: Adult; Anti-Dyskinesia Agents; Basal Ganglia; Brain Ischemia; Coma; Corpus Striatum; Drug Overdose; | 1997 |
Hemiballism-hemichorea from marked hypotension during spinal anesthesia.
Topics: Aged; Anesthesia, Spinal; Anti-Dyskinesia Agents; Chorea; Female; Haloperidol; Humans; Hypotension; | 1998 |
The effects of the atypical antipsychotic amperozide on vacuous jaw movements in rats: a novel dose response profile.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Ex | 1998 |
Postural effects of unilateral blockade of glutamatergic neurotransmission in the subthalamic nucleus on haloperidol-induced akinesia in rats.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Analysis of Variance; Animals; Anti-Dyskinesia Agents; Dizocil | 1998 |
Rapid-eye-movement sleep in jittery infants.
Topics: Female; Haloperidol; Humans; Infant; Male; Maternal-Fetal Exchange; Methyldopa; Movement Disorders; | 2002 |
Quantification of chorea in Huntington's disease by power spectral analysis.
Topics: Adult; Aged; Diazepam; Haloperidol; Humans; Huntington Disease; Mesoridazine; Methods; Middle Aged; | 1976 |
Modification of involuntary movements by centrally acting drugs.
Topics: Aminooxyacetic Acid; Animals; Atropine; Bicuculline; Bromocriptine; Dopamine; Haloperidol; Haplorhin | 1975 |
Neuroleptics, catecholamines, and psychoses: a study of their interrelations.
Topics: Adolescent; Adult; Brain; Brain Chemistry; Catecholamines; Chlorpromazine; Depression, Chemical; Dop | 1975 |
The treatment of the choreas and athetotic dystonias.
Topics: Adult; Athetosis; Benzodiazepines; Child; Chorea; Dystonia; Haloperidol; Humans; Levodopa; Movement | 1979 |
Acute dystonia as an idiosyncratic response to neuroleptics in baboons.
Topics: 5-Hydroxytryptophan; Acute Disease; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; H | 1977 |
Movement disorders induced in monkeys by chronic haloperidol treatment.
Topics: Animals; Behavior, Animal; Female; Haloperidol; Haplorhini; Movement Disorders; Saimiri; Time Factor | 1977 |
Therapeutic response in hemiballismus.
Topics: Aged; Female; Haloperidol; Humans; Movement Disorders; Remission, Spontaneous; Reserpine | 1979 |
Haloperidol plasma level monitoring in pediatric patients.
Topics: Adolescent; Adult; Aging; Child; Female; Haloperidol; Humans; Male; Movement Disorders; Psychotic Di | 1979 |
[Effect of phosphodiesterase inhibitors on neuroleptic-induced catalepsy and apomorphine-induced stereotypic movements in rats].
Topics: Animals; Apomorphine; Atropine; Catalepsy; Haloperidol; Humans; Movement Disorders; Papaverine; Phos | 1978 |
Effect of haloperidol on reflex activation of rat alpha-motoneurones. A possible explanation for akinesia and catalepsy?
Topics: Animals; Apomorphine; Catalepsy; Haloperidol; Humans; In Vitro Techniques; Male; Motor Neurons; Move | 1979 |
Methylphenidate-induced choreoathetosis.
Topics: Female; Haloperidol; Humans; Methapyrilene; Methylphenidate; Middle Aged; Movement Disorders; Physos | 1978 |
[Cerebral degenerative change in association with dyskinesia following neuroleptic treatment (author's transl)].
Topics: Female; Haloperidol; Humans; Middle Aged; Movement Disorders; Parkinson Disease; Parkinson Disease, | 1978 |
Haloperidol-induced tardive dyskinesia in monkeys.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Haplorhini; Macaca f | 1976 |
Letter: A bedtime story for nephrologists: The emperor's new molly-kules.
Topics: Diencephalon; Haloperidol; Humans; Movement Disorders | 1976 |
Letter: Response of hemiballismus to haloperidol.
Topics: Diencephalon; Female; Haloperidol; Humans; Middle Aged; Movement Disorders | 1976 |
Treatment and prognosis of hemiballismus.
Topics: Acute Disease; Aged; Chlorpromazine; Diencephalon; Dopamine; Feedback; Female; Haloperidol; Homovani | 1976 |
[Nigrostriatally induced motor reactions in the rat. I. Rotational behavior and posture asymetry after intracerebral injection of apomorphine and dopamine].
Topics: Animals; Apomorphine; Ascorbic Acid; Brain; Caudate Nucleus; Dopamine; Female; Haloperidol; Hydroxyd | 1976 |
Letter: Response of hemiballismus to haloperidol.
Topics: Aged; Diencephalon; Female; Haloperidol; Humans; Movement Disorders | 1976 |
[Effects of anticholinergics and clozapine on the activation of the striatal dopaminergic system in the rat by haloperidol. Pharmacological findings (author's transl)].
Topics: Animals; Apomorphine; Atropine; Clozapine; Corpus Striatum; Dibenzazepines; Dopamine; Drug Synergism | 1976 |
Atypical tardive dyskinesia.
Topics: Adult; Age Factors; Benztropine; Haloperidol; Humans; Male; Movement Disorders; Remission, Spontaneo | 1975 |
Role of the strio-pallidal system and motor cortex in induced circus movements in rats and cats.
Topics: Animals; Apomorphine; Brain Mapping; Cats; Chlorpromazine; Corpus Striatum; Dextroamphetamine; Drug | 1975 |
The acetylcholine-dopamine balance in the basal ganglia of rhesus monkeys and its role in dynamic, dystonic, dyskinetic, and epileptoid motor activities.
Topics: Acetylcholine; Animals; Atropine; Basal Ganglia; Carbachol; Caudate Nucleus; Dopamine; Drug Interact | 1975 |
Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine.
Topics: Animals; Apomorphine; Chlorpromazine; Clozapine; Corpus Striatum; Dibenzazepines; Dibenzoxazepines; | 1975 |
Response of hemiballismus to haloperidol.
Topics: Aged; Anxiety; Diencephalon; Drug Evaluation; Haloperidol; Humans; Male; Movement Disorders | 1975 |
Letter: No response of hemiballismus to haloperidol.
Topics: Aged; Diencephalon; Haloperidol; Humans; Male; Movement Disorders | 1975 |
Neuroleptics and the corpus striatum: clinical implications.
Topics: Acetylcholine; Basal Ganglia Diseases; Benztropine; Corpus Striatum; Dopamine; Fluphenazine; Haloper | 1976 |
Tardive dyskinesia.
Topics: Choline; Deanol; Dopamine Antagonists; Haloperidol; Humans; Methyldopa; Movement Disorders; Papaveri | 1976 |
[Hemiballism. Description of a clinical case in childhood].
Topics: Child, Preschool; Electroencephalography; Female; Haloperidol; Humans; Movement Disorders; Thalamus; | 1991 |
The rabbit syndrome.
Topics: Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Movement Disorders; Schizophre | 1990 |
Spontaneous orofacial dyskinesias in a captive cynomolgus monkey: implications for tardive dyskinesia.
Topics: Animals; Benzazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-In | 1990 |
Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Apomorphine; Avoidance Learning; Buspirone; Dopamin | 1989 |
Continued administration of GM1 ganglioside is required to maintain recovery from neuroleptic-induced sensorimotor deficits in MPTP-treated mice.
Topics: Animals; Brain Diseases; Catalepsy; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; G(M1) Gangl | 1989 |
Increased incidence and severity of neuroleptic-induced movement disorder in pinealectomized rats.
Topics: Animals; Antipsychotic Agents; Haloperidol; Male; Melatonin; Movement Disorders; Pineal Gland; Rats; | 1989 |
[Complex use of benzodiazepines, lithium salts and haloperidol in the treatment of obsessive movements and tics of different origin].
Topics: Adolescent; Anti-Anxiety Agents; Benzodiazepines; Child; Child, Preschool; Compulsive Behavior; Drug | 1987 |
Selective D1 and D2 receptor manipulation in Cebus monkeys: relevance for dystonia and dyskinesia in humans.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Benzazepi | 1987 |
Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder.
Topics: Acute Disease; Adolescent; Aggression; Akathisia, Drug-Induced; Antipsychotic Agents; Child; Child, | 1988 |
Administration of GM1 ganglioside eliminates neuroleptic-induced sensorimotor deficits in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Behavior, Animal; Corpu | 1988 |
Tourette's syndrome in Monroe County school children.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior; Child; Child, Preschool; Clonid | 1988 |
Paroxysmal myoclonic dystonia with vocalisations: new entity or variant of preexisting syndromes?
Topics: Adolescent; Adult; Child; Diagnosis, Differential; Dystonia; Female; Haloperidol; Humans; Male; Move | 1986 |
Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat.
Topics: Animals; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Female; Haloperidol; Levodop | 1987 |
Exacerbation of tardive dyskinesia by Joseph disease.
Topics: Aged; Brain Diseases; Cerebellar Ataxia; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Ment | 1986 |
[Hemiballism].
Topics: Aged; Cerebrovascular Disorders; Female; Haloperidol; Humans; Male; Middle Aged; Movement Disorders; | 1986 |
Bilateral ballism: a rare syndrome. Review of the literature and presentation of a case.
Topics: Adult; Cerebral Infarction; Electroencephalography; Female; Functional Laterality; Haloperidol; Huma | 1986 |
[Three cases of lingual ballistic movement followed by a rigid-dystonic state of the tongue].
Topics: Aged; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Movement | 1985 |
New dystonic syndrome associated with butyrophenone therapy.
Topics: Amines; Antiparkinson Agents; Basal Ganglia; Butyrophenones; Dementia; Female; Gait; Haloperidol; Hu | 1972 |
Blockade by apomorphine of haloperidol-induced dyskinesia in schizophrenic patients.
Topics: Adult; Apomorphine; Haloperidol; Humans; Male; Movement Disorders; Schizophrenia | 1972 |
Dystonic reactions to drugs.
Topics: Antipsychotic Agents; Corpus Striatum; Dopamine; Drug Interactions; Haloperidol; Humans; Movement Di | 1973 |
Antiparkinson drugs as causal agents in tardive dyskinesia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Benztropine; Drug Synergism; Female; Fluphenazine; Halop | 1973 |
Maintenance treatment of schizophrenia with long-acting fluphenazine.
Topics: Adult; Chlorpromazine; Delayed-Action Preparations; Female; Fluphenazine; Haloperidol; Humans; Movem | 1974 |
Dopaminergic and cholinergic mechanisms in relation to postural tremor in the monkey and circling movements in the cat.
Topics: Acetylcholine; Amphetamine; Animals; Cats; Corpus Striatum; Disease Models, Animal; Dopamine; Fronta | 1974 |
[Use of haloperidol in the treatment of extrapyramidal compulsive movement].
Topics: Adult; Aged; Chorea; Extrapyramidal Tracts; Female; Haloperidol; Humans; Huntington Disease; Hyperki | 1970 |
Lingual-facial-buccal movements in the elderly. I. Pathophysiology and treatment.
Topics: Aged; Amphetamine; Chemoreceptor Cells; Chlorpromazine; Corpus Striatum; Dopamine Antagonists; Facia | 1973 |
Drug treatment of diseases characterized by abnormal movements.
Topics: Chorea; Diazepam; Ethanol; Haloperidol; Humans; Huntington Disease; Levodopa; Movement Disorders; My | 1973 |
Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour.
Topics: Amphetamine; Animals; Apomorphine; Brain; Butyrophenones; Dopamine; Electrocoagulation; Haloperidol; | 1971 |
Mescaline: receptor interaction in the rat striatum.
Topics: Animals; Basal Ganglia; Behavior, Animal; Caudate Nucleus; Chlorpromazine; Cyclic AMP; Dopamine; Dru | 1972 |
Drug-induced syndromes in rats with large, chronic lesions in the corpus striatum.
Topics: Amphetamine; Animals; Apomorphine; Basal Ganglia; Behavior, Animal; Brain; Globus Pallidus; Haloperi | 1972 |
The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy.
Topics: Adult; Aged; Brain Damage, Chronic; Cheek; Chlorpromazine; Chlorprothixene; Clopenthixol; Female; Ha | 1967 |
[Affective disorders in the course of treatment with neuroleptics of children and adolescents with schizophrenia].
Topics: Adolescent; Affect; Child; Child, Preschool; Chlorpromazine; Depression; Haloperidol; Humans; Moveme | 1967 |
[Study of extrapyramidal manifestations induced by neuroleptics].
Topics: Antiparkinson Agents; Chlorpromazine; Drug Synergism; Extrapyramidal Tracts; Fluphenazine; Haloperid | 1972 |
To the incompatibility of haloperidol with lithium salts.
Topics: Adolescent; Bipolar Disorder; Drug Incompatibility; Drug Therapy, Combination; Female; Haloperidol; | 1974 |
Clinical features, etiology and treatment of facial dyskinesias in the elderly.
Topics: Age Factors; Aged; Brain; Brain Damage, Chronic; Brain Stem; Chorea; Dementia; Dopamine; Face; Femal | 1974 |
Letter: Reversible dyskinesis caused by haloperidol.
Topics: Adolescent; Female; Haloperidol; Humans; Movement Disorders; Schizophrenia | 1974 |
Lithium carbonate, haloperidol, and irreversible brain damage.
Topics: Acute Disease; Adult; Bipolar Disorder; Brain; Brain Diseases; Carbonates; Chronic Disease; Consciou | 1974 |
Differential diagnosis of Gilles de la Tourette's syndrome.
Topics: Adolescent; Adult; Child; Child, Preschool; Diagnosis, Differential; Diffuse Cerebral Sclerosis of S | 1972 |
Treatment of Tourette's syndrome with haloperidol, review of 34 cases.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Child; Depression; Evaluation Studies as Topic; Female; F | 1973 |
[Case of bucco-lingual dyskinesia].
Topics: Aged; Haloperidol; Humans; Lip Diseases; Male; Masticatory Muscles; Movement Disorders; Tongue Disea | 1972 |
Haloperidol: fifteen years of clinical experience.
Topics: Antiemetics; Basal Ganglia Diseases; Bipolar Disorder; Female; Haloperidol; Humans; Mental Disorders | 1972 |
Structure side-effect sorting of drugs. I. Extrapyramidal syndrome.
Topics: Anticonvulsants; Basal Ganglia Diseases; Benzamides; Computers; Diazepam; Drug-Related Side Effects | 1973 |
Rapid reversal of tardive dyskinesia.
Topics: Adult; Chlorpromazine; Dibenzoxepins; Female; Haloperidol; Humans; Movement Disorders; Neurologic Ma | 1973 |
Letter: Delayed drug-induced dystonias.
Topics: Haloperidol; Humans; Male; Movement Disorders; Muscle Tonus; Muscular Diseases; Procyclidine; Time F | 1973 |
Tardive and withdrawal dyskinesia associated with haloperidol.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Butyrophenones; Dose-Response Relationship, Drug; Female; | 1974 |
Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias.
Topics: Adult; Aged; Dihydroxyphenylalanine; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; M | 1974 |
Haloperidol in the treatment of dyskinesias.
Topics: Adolescent; Adult; Child; Chorea; Diencephalon; Female; Haloperidol; Hepatolenticular Degeneration; | 1974 |
Role of noradrenaline in levodopa reversal of reserpine akinesia.
Topics: Animals; Chlorpromazine; Dihydroxyphenylalanine; Haloperidol; Mice; Movement Disorders; Norepinephri | 1974 |
Observations on the effect of levodopa on tardive lingual-facial-buccal dyskinesia.
Topics: Aged; Chlorpromazine; Dihydroxyphenylalanine; Dopamine; Facial Muscles; Female; Haloperidol; Humans; | 1971 |
Tourette's disease: control of symptoms and its clinical course.
Topics: Adolescent; Child; Child, Preschool; Female; Haloperidol; Handwriting; Humans; Male; Motor Activity; | 1967 |
Psychoactive agents in dogs with bilateral lesions in subcortical structures.
Topics: 5-Hydroxytryptophan; Animals; Caudate Nucleus; Chlorpromazine; Dogs; Dopamine; Haloperidol; Hippocam | 1971 |
[Complex persisting dyskinesia, secondary to neuroleptic therapy].
Topics: Aged; Butyrophenones; Delirium; Electromyography; Extrapyramidal Tracts; Female; Haloperidol; Humans | 1969 |
[Influencing of biological and immunologic pregnancy reactions by psychotropic drugs].
Topics: Adolescent; Adult; Aged; Butyrophenones; Chlorpromazine; Dementia; Depressive Disorder, Major; Dysau | 1969 |
[A chronic extrapyramidal syndrome as a complication of neuroleptic therapy].
Topics: Aged; Bipolar Disorder; Chlorpromazine; Chronic Disease; Extrapyramidal Tracts; Female; Haloperidol; | 1969 |
[Haloperidol in the treatment of hyperkinetic syndromes].
Topics: Adult; Aged; Chorea; Female; Haloperidol; Humans; Male; Middle Aged; Movement Disorders; Parkinson D | 1970 |
Intramuscular long-acting fluphenazine in the treatment of schizophrenia.
Topics: Administration, Oral; Adult; Aged; Chlorpromazine; Chronic Disease; Fluphenazine; Haloperidol; Human | 1970 |
The treatment of dystonia with L-dopa and haloperidol.
Topics: Adolescent; Adult; Child; Dihydroxyphenylalanine; Dystonia Musculorum Deformans; Female; Haloperidol | 1970 |
Importance and pathogenesis of abnormal movements during L-dopa therapy of Parkinson's disease.
Topics: Administration, Oral; Animals; Dihydroxyphenylalanine; Haloperidol; Humans; Movement Disorders; Musc | 1970 |
[Periodic hypersomnia with megaphagia in adolescent males: Kleine-Levin syndrome. A case with an electroencephalographic study and comments].
Topics: Adolescent; Electroencephalography; Haloperidol; Humans; Hunger; Male; Movement Disorders; Sleep Wak | 1967 |
[On the problem of the therapeutical axis symptom of neuroleptic medicaments].
Topics: Adult; Extrapyramidal Tracts; Fluphenazine; Haloperidol; Handwriting; Humans; Male; Movement Disorde | 1968 |
[Central and peripheral secondary effects of some butyrophenones].
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Benperidol; Butyrophenones; Central Nervous System; | 1969 |
[A case of chronic piperazine abuse].
Topics: Adult; Bipolar Disorder; Haloperidol; Humans; Male; Movement Disorders; Piperazines; Substance-Relat | 1965 |